Drug intelligence / Profile preview

EcN-Mel

Development stage: Preclinical
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

EcN-Mel is an engineered probiotic derived from genetically modified Nissle 1917 Escherichia coli that expresses tyrosinase genes. This modification enables the bacteria to produce and secrete melanin. The melanin acts as a nanozyme, effectively scavenging reactive oxygen species, particularly at colitis lesions. EcN-Mel also works by modulating the gut microbiota, enhancing beneficial bacteria like Lactobacillus while decreasing harmful Proteobacteria, promoting gut microbiota homeostasis. Furthermore, it contributes to cytokine regulation and intestinal barrier restoration, collectively alleviating intestinal mucosal damage. It is being developed for the oral treatment of Ulcerative Colitis.

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on EcN-Mel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcN-Mel.

Explore the full profile